Birchview Capital, LP Buys Aspira Womens Health Inc, bluebird bio Inc, Equitrans Midstream Corp, Sells ContraFect Corp, Gilead Sciences Inc, EQM Midstream Partners LP

• New Purchases: CUL1, BLUE, ETRN, MYOK, CLR, NARI, OVV,
• Added Positions: AMRN, NBIX, QDEL, KPTI, EPZM, ACAD,
• Reduced Positions: GILD, IFRX, WKHS,
• Sold Out: CFRX, EQM,

For the details of Birchview Capital, LP's stock buys and sells, go to https://www.gurufocus.com/guru/birchview+capital%2C+lp/current-portfolio/portfolio

1. Bristol-Myers Squibb Company (BMY) - 792,386 shares, 28.78% of the total portfolio. Shares added by 0.84%
2. Accelerate Diagnostics Inc (AXDX) - 2,193,795 shares, 20.55% of the total portfolio.
3. Aspira Womens Health Inc (CUL1) - 3,297,247 shares, 7.82% of the total portfolio. New Position
4. Quidel Corp (QDEL) - 50,944 shares, 7.04% of the total portfolio. Shares added by 4.30%
5. Neurocrine Biosciences Inc (NBIX) - 78,000 shares, 5.88% of the total portfolio. Shares added by 5.41%

Birchview Capital, LP initiated holding in Aspira Womens Health Inc. The purchase prices were between $0.69 and $4.8, with an estimated average price of $2.25. The stock is now traded at around $2.16. The impact to a portfolio due to this purchase was 7.82%. The holding were 3,297,247 shares as of .

Birchview Capital, LP initiated holding in bluebird bio Inc. The purchase prices were between $41.88 and $70.98, with an estimated average price of $57.98. The stock is now traded at around $56.88. The impact to a portfolio due to this purchase was 2.26%. The holding were 60,000 shares as of .

Birchview Capital, LP initiated holding in Equitrans Midstream Corp. The purchase prices were between $4.93 and $9.66, with an estimated average price of $7.8. The stock is now traded at around $8.51. The impact to a portfolio due to this purchase was 0.68%. The holding were 133,050 shares as of .

Birchview Capital, LP initiated holding in MyoKardia Inc. The purchase prices were between $44.2 and $121.69, with an estimated average price of $82.77. The stock is now traded at around $132.01. The impact to a portfolio due to this purchase was 0.6%. The holding were 10,000 shares as of .

Birchview Capital, LP initiated holding in Continental Resources Inc. The purchase prices were between $7.47 and $21.58, with an estimated average price of $13.92. The stock is now traded at around $12.84. The impact to a portfolio due to this purchase was 0.42%. The holding were 38,600 shares as of .

Birchview Capital, LP initiated holding in Inari Medical Inc. The purchase prices were between $42.51 and $52.46, with an estimated average price of $47.57. The stock is now traded at around $65.12. The impact to a portfolio due to this purchase was 0.3%. The holding were 10,000 shares as of .

Birchview Capital, LP added to a holding in Amarin Corp PLC by 44.44%. The purchase prices were between $4 and $8.26, with an estimated average price of $6.83. The stock is now traded at around $3.77. The impact to a portfolio due to this purchase was 0.34%. The holding were 260,000 shares as of .

Birchview Capital, LP sold out a holding in ContraFect Corp. The sale prices were between $4.69 and $7.81, with an estimated average price of $6.12.

Birchview Capital, LP sold out a holding in EQM Midstream Partners LP. The sale prices were between $11.65 and $23.43, with an estimated average price of $18.44.

Birchview Capital, LP reduced to a holding in Gilead Sciences Inc by 50%. The sale prices were between $72.34 and $84, with an estimated average price of $76.51. The stock is now traded at around $62.25. The impact to a portfolio due to this sale was -0.67%. Birchview Capital, LP still held 10,000 shares as of .

Birchview Capital, LP reduced to a holding in InflaRx NV by 36.36%. The sale prices were between $3.82 and $8.96, with an estimated average price of $6.45. The stock is now traded at around $4.47. The impact to a portfolio due to this sale was -0.13%. Birchview Capital, LP still held 70,000 shares as of .

Birchview Capital, LP reduced to a holding in Workhorse Group Inc by 40%. The sale prices were between $1.63 and $17.39, with an estimated average price of $3.55. The stock is now traded at around $24.68. The impact to a portfolio due to this sale was -0.02%. Birchview Capital, LP still held 15,000 shares as of .